Sandra Calvin Sells 67,115 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 67,115 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the sale, the chief accounting officer directly owned 48,545 shares of the company’s stock, valued at $1,747,620. The trade was a 58.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock traded down $0.48 on Thursday, hitting $33.24. The stock had a trading volume of 1,328,190 shares, compared to its average volume of 1,824,398. Travere Therapeutics, Inc. has a 52-week low of $12.91 and a 52-week high of $36.15. The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 9.50. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -16.29 and a beta of 0.83. The company’s 50 day moving average price is $25.50 and its 200 day moving average price is $19.78.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 717.68% and a negative net margin of 50.64%.The business had revenue of $113.15 million during the quarter, compared to the consensus estimate of $106.09 million. During the same period in the previous year, the business earned ($0.70) EPS. The business’s quarterly revenue was up 162.1% on a year-over-year basis. On average, research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. First Horizon Corp purchased a new position in shares of Travere Therapeutics in the 3rd quarter worth $36,000. Raymond James Financial Inc. purchased a new position in shares of Travere Therapeutics in the 2nd quarter worth $33,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Travere Therapeutics in the 1st quarter worth $62,000. KBC Group NV purchased a new position in shares of Travere Therapeutics in the 1st quarter worth $75,000. Finally, Headlands Technologies LLC purchased a new position in shares of Travere Therapeutics in the 2nd quarter worth $73,000.

Analyst Ratings Changes

A number of analysts have weighed in on TVTX shares. Zacks Research raised Travere Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. TD Cowen increased their price objective on Travere Therapeutics from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Citigroup increased their price objective on Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Wall Street Zen raised Travere Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, October 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.71.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.